The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Open accessAbstract
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus primary disease. Metastatic tumors were enriched for proliferation-related and migration-related genes and diminished for luminal-related genes. Expression of proliferation-related genes were better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at predicting OSmet in primary disease compared with metastatic tissue. We observed correlations between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment. Cancer Res; 77(9); 2213–21. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540 · cited 1×
“Despite new systemic treatment advances, metastatic breast cancer is still an incurable disease and a major cause of cancer-related death (1).”
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
Cited by
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M., Connor, A. A., Denroche, R. E., Grant, R. C., McLeod, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0566-9 · Cited by 669
Breast Cancer: Multiple Subtypes within a Tumor?
Yeo, S. K., & Guan, J.-L. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.09.001 · Cited by 402
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13112824 · Cited by 267
Metadata
- Authors
- Cejalvo, J. M., Martínez de Dueñas, E., Galván, P., García-Recio, S., Burgués Gasión, O., Paré, L., Antolín, S., Martinello, R., Blancas, I., Adamo, B., Guerrero-Zotano, Á., Muñoz, M., Nucíforo, P., Vidal, M., Pérez, R. M., Chacón López-Muniz, J. I., Caballero, R., Peg, V., Carrasco, E., Rojo, F., Perou, C. M., Cortés, J., Adamo, V., Albanell, J., Gomis, R. R., Lluch, A., & Prat, A.
- Venue
- Cancer Research
- Published
- 2017-04-30
- Volume
- 77
- Issue
- 9
- Pages
- 2213-2221
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2591810315
- Cited by
- 245
- References
- 7
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2717
- The paper
- Cejalvo, J. M., Martínez de Dueñas, E., Galván, P., García-Recio, S., Burgués Gasión, O., Paré, L., Antolín, S., Martinello, R., Blancas, I., Adamo, B., Guerrero-Zotano, Á., Muñoz, M., Nucíforo, P., Vidal, M., Pérez, R. M., Chacón López-Muniz, J. I., Caballero, R., Peg, V., Carrasco, E., . . . Prat, A. (2017). Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.